What SEC filings does Denali Therapeutics Inc. submit to the SEC?

Denali Therapeutics Inc. (DNLI) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about DNLI?

A Form 4 for DNLI discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Denali Therapeutics Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for DNLI?

The 10-K is Denali Therapeutics Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all DNLI SEC filings directly on EDGAR?

You can view all historical Denali Therapeutics Inc. filings on the SEC EDGAR company page for DNLI. Each filing card on this page links directly to the original SEC document.

How often does Denali Therapeutics Inc. file with the SEC?

Denali Therapeutics Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling DNLI shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

DNLI SEC Filing News — Denali Therapeutics Inc.

Latest SEC filings for Denali Therapeutics Inc. (DNLI) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-09.

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement thera…

Sector: Healthcare Industry: Biotechnology Market Cap: $3.0B

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for DNLI currently lean bearish. Of the 20 filing records displayed, 4 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

DNLI Filing Activity Snapshot 2026-06-05 — 2026-09-09

Insider Transactions (Form 4)

0 buys vs 4 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$266.1K

NANCY THORNBERRY · 2026-09-02

11,439 shares · Form 144

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 12 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 12 filings in this group are Form 4s for Denali Therapeutics Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 12 insider filings shown, the breakdown is 7 compensation award, 4 open-market sale and 1 gift. 4 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×7: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market sale ×4: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Gift ×1: Shares were transferred as a gift, typically for estate or charitable planning. No sale into the market took place.

Form 4 Open-market sale Insider Selling 2026-09-09

DNLI insider Chin Peter Scott (Chief Medical Officer) sold 1,654 shares (~$36.9K)

Chin Peter Scott, listed as Chief Medical Officer at Denali Therapeutics Inc., reported an open-market sale of 1,654 DNLI shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	1,654	$22.29	$36.9K

Filing: Form 4 (Insider Transaction) Insider: Chin Peter Scott (Chief Medical Officer) Shares: 1,654 Est. Value: $36.9K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-04

DNLI insider Thornberry Nancy (Director) sold 11,439 shares (~$261.9K)

Thornberry Nancy, listed as Director at Denali Therapeutics Inc., reported an open-market sale of 11,439 DNLI shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	10,824	$22.85	$247.3K
`S`	Open-market sale	615	$23.74	$14.6K

Filing: Form 4 (Insider Transaction) Insider: Thornberry Nancy (Director) Shares: 11,439 Est. Value: $261.9K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-03

DNLI insider Schuth Alexander O. (COFO and Secretary) sold 2,768 shares (~$64.9K)

Schuth Alexander O., listed as COFO and Secretary at Denali Therapeutics Inc., reported an open-market sale of 2,768 DNLI shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	2,768	$23.44	$64.9K

Filing: Form 4 (Insider Transaction) Insider: Schuth Alexander O. (COFO and Secretary) Shares: 2,768 Est. Value: $64.9K

View on SEC EDGAR → Open Filing Document →

Form 4 Gift Tax / Compensation Filing 2026-08-14

DNLI insider Form 4 filed for equity award, exercise, or tax withholding

Watts Ryan J. (Director, President and CEO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were transferred as a gift, typically for estate or charitable planning. No sale into the market took place.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`G`	Gift	32,220	—	—

Filing: Form 4 (Insider Transaction) Insider: Watts Ryan J. (Director, President and CEO) Shares: 32,220

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-08-13

DNLI insider Schuth Alexander O. (COFO and Secretary) sold 2,857 shares (~$71.6K)

Schuth Alexander O., listed as COFO and Secretary at Denali Therapeutics Inc., reported an open-market sale of 2,857 DNLI shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	2,857	$25.07	$71.6K

Filing: Form 4 (Insider Transaction) Insider: Schuth Alexander O. (COFO and Secretary) Shares: 2,857 Est. Value: $71.6K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-05

DNLI insider Form 4 filed for equity award, exercise, or tax withholding

FLATLEY JAY T (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	6,408	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	19,226	—	—

Filing: Form 4 (Insider Transaction) Insider: FLATLEY JAY T (Director) Shares: 6,408

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-05

DNLI insider Form 4 filed for equity award, exercise, or tax withholding

Klein Peter S (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	6,408	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	19,226	—	—

Filing: Form 4 (Insider Transaction) Insider: Klein Peter S (Director) Shares: 6,408

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-05

DNLI insider Form 4 filed for equity award, exercise, or tax withholding

Krognes Steve E. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	6,408	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	19,226	—	—

Filing: Form 4 (Insider Transaction) Insider: Krognes Steve E. (Director) Shares: 6,408

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-05

DNLI insider Form 4 filed for equity award, exercise, or tax withholding

Schenkein David P (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	6,408	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	19,226	—	—

Filing: Form 4 (Insider Transaction) Insider: Schenkein David P (Director) Shares: 6,408

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-05

DNLI insider Form 4 filed for equity award, exercise, or tax withholding

Thornberry Nancy (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	6,408	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	19,226	—	—

Filing: Form 4 (Insider Transaction) Insider: Thornberry Nancy (Director) Shares: 6,408

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-05

DNLI insider Form 4 filed for equity award, exercise, or tax withholding

Van Hauwermeiren Timothy (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	6,408	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	19,226	—	—

Filing: Form 4 (Insider Transaction) Insider: Van Hauwermeiren Timothy (Director) Shares: 6,408

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-05

DNLI insider Form 4 filed for equity award, exercise, or tax withholding

Cook Jennifer E. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	6,408	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	19,226	—	—

Filing: Form 4 (Insider Transaction) Insider: Cook Jennifer E. (Director) Shares: 6,408

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 4 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Denali Therapeutics Inc. has 4 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-09-04

DNLI Form 144 filed for proposed insider sale by Chin Peter Scott (1,654 shares) ~$36.9K

Chin Peter Scott filed a Form 144 with the SEC indicating intent to sell DNLI (Denali Therapeutics Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Chin Peter Scott Shares: 1,654 Est. Value: $36.9K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-09-02

DNLI Form 144 filed for proposed insider sale by NANCY THORNBERRY (11,439 shares) ~$266.1K

NANCY THORNBERRY filed a Form 144 with the SEC indicating intent to sell DNLI (Denali Therapeutics Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: NANCY THORNBERRY Shares: 11,439 Est. Value: $266.1K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-09-01

DNLI Form 144 filed for proposed insider sale by ALEXANDER SCHUTH (2,768 shares) ~$65.8K

ALEXANDER SCHUTH filed a Form 144 with the SEC indicating intent to sell DNLI (Denali Therapeutics Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: ALEXANDER SCHUTH Shares: 2,768 Est. Value: $65.8K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-08-11

DNLI Form 144 filed for proposed insider sale by Schuth Alexander O. (2,857 shares) ~$71.6K

Schuth Alexander O. filed a Form 144 with the SEC indicating intent to sell DNLI (Denali Therapeutics Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Schuth Alexander O. Shares: 2,857 Est. Value: $71.6K

View on SEC EDGAR → Open Filing Document →

Material Events 3 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 3 in this period for Denali Therapeutics Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-06

DNLI filed 8-K — material company event

Denali Therapeutics Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-07-28

DNLI filed 8-K — material company event

Denali Therapeutics Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-06-18

DNLI filed 8-K — material company event

Denali Therapeutics Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Denali Therapeutics Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-06

DNLI filed Quarterly Report (10-Q)

Denali Therapeutics Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

How we classify Denali Therapeutics Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on DNLI. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — DNLI SEC Filings

More Tools for DNLI

DNLI Full Stock Analysis DNLI Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper DNLI analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the DNLI stock analysis page.

DNLI Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer